These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33347711)

  • 41. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
    Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS
    Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanomedicine and drug delivery systems in cancer and regenerative medicine.
    Garbayo E; Pascual-Gil S; Rodríguez-Nogales C; Saludas L; Estella-Hermoso de Mendoza A; Blanco-Prieto MJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1637. PubMed ID: 32351045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients.
    Chariou PL; Ortega-Rivera OA; Steinmetz NF
    ACS Nano; 2020 Mar; 14(3):2678-2701. PubMed ID: 32125825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual and multi-targeted nanoparticles for site-specific brain drug delivery.
    Luo Y; Yang H; Zhou YF; Hu B
    J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic drug delivery systems for bone tissue regeneration- a mini review.
    Xinluan W; Yuxiao L; Helena NH; Zhijun Y; Ling Q
    Curr Pharm Des; 2015; 21(12):1575-83. PubMed ID: 25594406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements.
    Van't Root M; Lowik C; Mezzanotte L
    Curr Pharm Des; 2017; 23(13):1953-1962. PubMed ID: 28025944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanoparticles for Cancer Targeting: Current and Future Directions.
    Swain S; Sahu PK; Beg S; Babu SM
    Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone Targeting Nanoparticles for the Treatment of Osteoporosis.
    Wen C; Xu X; Zhang Y; Xia J; Liang Y; Xu L
    Int J Nanomedicine; 2024; 19():1363-1383. PubMed ID: 38371454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.
    Huang X; Wu W; Yang W; Qing X; Shao Z
    Colloids Surf B Biointerfaces; 2020 Jun; 190():110891. PubMed ID: 32114271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanocarrier-based drug delivery systems for bone cancer therapy: a review.
    Prasad SR; Kumar TSS; Jayakrishnan A
    Biomed Mater; 2021 May; 16(4):. PubMed ID: 33853043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD44 targeted PLGA nanomedicines for cancer chemotherapy.
    Saneja A; Arora D; Kumar R; Dubey RD; Panda AK; Gupta PN
    Eur J Pharm Sci; 2018 Aug; 121():47-58. PubMed ID: 29777858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Nano-War Against Complement Proteins.
    Wang Z; Brenner JS
    AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
    Shi P; Cheng Z; Zhao K; Chen Y; Zhang A; Gan W; Zhang Y
    J Nanobiotechnology; 2023 Mar; 21(1):103. PubMed ID: 36944946
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.